

## **Teva Pharmaceuticals Limited**

Registered number: 01077587

### **Annual report and financial statements for the year ended 31 December 2016**



# **Teva Pharmaceuticals Limited**

## **Annual report and financial statements for the year ended 31 December 2016**

### **Contents**

	<b>Page</b>
Directors and advisers.....	1
Directors' report for the year ended 31 December 2016.....	2
Balance sheet as at 31 December 2016.....	3
Notes to the financial statements.....	4

# **Teva Pharmaceuticals Limited**

## **Directors and advisers**

### **Directors**

R Williams  
K Innes  
D Vrhovec

### **Registered office**

Ridings Point  
Whistler Drive  
Castleford  
West Yorkshire  
WF10 5HX

### **Registered number**

01077587

# **Teva Pharmaceuticals Limited**

## **Directors' report for the year ended 31 December 2016**

The directors present their annual report and the audited financial statements of the company for the year ended 31 December 2016.

### **Principal Activities**

The company did not trade during the year.

### **Results and dividends**

The company's profit for the current year was £ nil (2015: Nil). The directors do not recommend the payment of a dividend (2015: £ Nil).

### **Business review and future developments**

Teva Pharmaceuticals Limited is dormant and has not traded during the current or prior year. The company received no income and incurred no expenditure and therefore made neither a profit nor a loss.

### **Directors**

The directors of the company during the year and up to the date of signing the financial statements were as follows:

R Williams	(appointed 18 March 2016)
K Innes	(appointed 27 September 2016)
D Vrhovec	(appointed 1 May 2016)
R Daniell	(appointed 18 March 2016; resigned 27 September 2016)
M Schrewe	(resigned 1 August 2016)
S Oldfield	(resigned 18 March 2016)
T Oreskovic	(resigned 14 January 2016)

### **Directors' Indemnities**

The directors and officers of the Company are covered by liability insurance arranged by the ultimate parent company Teva Pharmaceutical Industries Limited. The insurance contains qualifying third party indemnity provisions for the purposes of the Companies Act 2006 and was in place during the year and up to the date of signing the financial statements.

On behalf of the board



R Williams  
**Director**

12 June 2017

# Teva Pharmaceuticals Limited

## Balance sheet as at 31 December 2016


	Note	2016 £'000	2015 £'000
<b>Current assets</b>			
Debtors	4	4,684	4,684
<b>Net current assets and net assets</b>		<b>4,684</b>	<b>4,684</b>
<b>Capital and reserves</b>			
Called up share capital	5	-	-
Profit and loss account	6	4,684	4,684
<b>Total equity shareholders' funds</b>	7	<b>4,684</b>	<b>4,684</b>

For the year ended 31 December 2016, the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

### Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 of the Companies Act 2006;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

The financial statements on pages 3 to 5 were approved by the board of directors on 12 June 2017 and were signed on its behalf by:



R Williams  
Director

Registered number 01077587

# Teva Pharmaceuticals Limited

## Notes to the financial statements for the year ended 31 December 2016

### 1 Significant accounting policies

The financial statements are prepared under the historical cost convention on the going concern basis and in accordance with the Companies Act 2006 and applicable accounting standards in the United Kingdom. The principal accounting policies are set out below and have been consistently applied throughout the current and prior year.

The company has taken advantage of the transitional provisions available to dormant companies in accordance with Financial Reporting Standard 102 (FRS 102) issued by the Financial Reporting Council. The company has elected to retain its accounting policies for measurement of assets, liabilities and equity until the balances change or the company undertakes any new transactions.

The company is included by full consolidation in the consolidated financial statements of its ultimate parent company, Teva Pharmaceutical Industries Limited, a company incorporated in Israel and whose financial statements are publicly available from the address in note 9. Consequently, the company is also exempt under the terms of FRS 1, 'Cash flow statements', from publishing a cash flow statement.

### 2 Operating profit

The company did not trade during the financial year and consequently made neither a profit nor a loss for the year.

### 3 Employees and directors' remuneration

The directors received no emoluments in the year in respect of their services as directors of the company (2015: £nil). The company had no other employees during the year (2015: none).

### 4 Debtors

	2016 £'000	2015 £'000
Amounts owed by group undertakings	4,684	4,684

Amounts owed by group undertakings are unsecured, interest-free and are repayable on demand.

### 5 Called up share capital

	2016 £	2015 £
<b>Authorised</b>		
200 (2015: 200) ordinary shares of £1 each	200	200
<b>Allotted, and fully paid</b>		
200 (2015: 200) ordinary shares of £1 each	200	200

# Teva Pharmaceuticals Limited

## Notes to the financial statements for the year ended 31 December 2016 (continued)

### 6 Profit and loss account

	£'000
At 1 January 2016	4,684
Profit for the financial year	-
<b>At 31 December 2016</b>	<b>4,684</b>

### 7 Reconciliation of movement in shareholders' funds

	2016	2015
	£'000	£'000
<b>At 31 December 2016 and at 1 January 2016</b>	<b>4,684</b>	<b>4,684</b>

### 8 Related party transactions

The company is a wholly owned subsidiary of Teva Pharmaceutical Industries Limited whose consolidated financial statements are publicly available for inspection from the address in note 9. Consequently the company has taken advantage of the exemption available under the terms of FRS 8 not to disclose related party transactions with group companies.

### 9 Ultimate parent undertaking and controlling party

The company's immediate parent undertaking is Teva UK Holdings Limited incorporated in England and Wales. The directors regard Teva Pharmaceutical Industries Limited, a company incorporated in Israel, as the ultimate parent company and ultimate controlling party.

Teva Pharmaceutical Industries Limited is the parent undertaking of the largest and smallest group of undertakings to consolidate these financial statements at 31 December 2016. The consolidated financial statements of Teva Pharmaceutical Industries Limited can be obtained from 5 Basel St., Petach Tikva 49131, Israel.